세계의 혈장 유도체 시장 보고서(2025년)
Blood Plasma Derivatives Global Market Report 2025
상품코드 : 1824344
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,516,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,419,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,322,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

혈장 유도체 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년 연평균 복합 성장률(CAGR)은 9.1%를 나타내 790억 9,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 희귀질환 치료의 출현, 만성 질환 증가, 건강 관리 지출 증가, 환자 중심의 치료 접근법, 건강 관리 인프라의 성장에 기인합니다. 예측 기간의 주요 동향으로는 분획기술의 진보, 환자 중심의 어프로치, 공동연구·제휴, 신경학에서의 응용확대, 혈장분획의 기술 혁신 등을 들 수 있습니다.

향후 5년간의 성장률 9.1%라고 하는 예측은 이 시장의 전회 예측으로부터의 0.2%라고 하는 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 인상은 오스트리아와 스페인에서 공급되는 면역글로불린 치료제와 알부민 용액의 비용을 끌어올려 면역 결핍증의 치료비를 악화시키고 전문 약국의 지출을 증가시킴으로써 미국 환자에게 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

면역 결핍증의 이환율 증가는 혈장 유도체 시장 성장을 가속할 것으로 예측됩니다. 면역결핍 장애는 면역계가 전체적으로 또는 부분적으로 약해지는 질환입니다. 혈장 유도체는 면역결핍 장애를 포함한 다양한 병리학의 치료에 이용됩니다. 단백질과 염으로 구성된 혈장에는 100가지 이상의 단백질이 포함되어 있으며, 특히 면역글로불린은 원발성 면역결핍의 치료에 중요합니다. 영양실조와 영양실조 등의 요인은 거시영양소나 미량영양소의 결핍을 초래하여 면역 결핍을 일으킵니다. 예를 들어, 2022년 3월, 알레르기, 천식, 임상 면역학(Allergy, Asthma & Clinical Immunology)은 가장 유행한 질환은 공통 변종성 면역 결핍증(CVID)이며, 미국에서는 16.6%, 국제적으로는 12.9%, 전 세계적으로 13.9%의 개인에게 영향을 미쳤습니다. 따라서 면역결핍 질환의 유병률 증가는 혈장 유도체 시장 성장에 기여합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Blood plasma derivatives are pharmaceutical products derived from refined proteins found in blood plasma, including clotting factors, albumins, and other proteins. These derivatives play a crucial role in medical treatment by replenishing deficient or absent proteins within the body.

The primary types of blood plasma derivatives include albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. Albumin is a key protein present in these derivatives, contributing to the regulation of osmotic pressure in the blood and aiding in the transportation of hormones, metals, and other molecules throughout the body. These derivatives find application in various medical conditions such as hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's disease, and more. They are utilized by diverse end-users, including hospitals, clinics, and other healthcare institutions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The blood plasma derivatives market research report is one of a series of new reports from The Business Research Company that provides blood plasma derivatives market statistics, including blood plasma derivatives industry global market size, regional shares, competitors with a blood plasma derivatives market share, detailed blood plasma derivatives market segments, market trends and opportunities, and any further data you may need to thrive in the blood plasma derivatives industry. This blood plasma derivatives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The blood plasma derivatives market size has grown strongly in recent years. It will grow from $51.81 billion in 2024 to $55.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increased prevalence of hemophilia and bleeding disorders, growth in geriatric population, increased awareness and diagnosis, rise in surgical procedures, global blood transfusion services.

The blood plasma derivatives market size is expected to see strong growth in the next few years. It will grow to $79.09 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to emergence of rare diseases therapies, growth in chronic diseases, increasing healthcare expenditure, patient-centric treatment approaches, growing healthcare infrastructure. Major trends in the forecast period include advancements in fractionation technologies, patient-centric approaches, collaborations and partnerships, expanding applications in neurology, technological innovations in plasma fractionation.

The forecast of 9.1% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of immunoglobulin therapies and albumin solutions sourced from Austria and Spain, exacerbating treatment costs for immunodeficiencies and raising specialty pharmacy expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of immunodeficiency disorders is anticipated to drive the growth of the blood plasma derivatives market. Immunodeficiency disorders are conditions that either fully or partially weaken the immune system. Blood plasma derivatives are utilized in the treatment of various medical conditions, including immune deficiency disorders. Plasma, which is composed of proteins and salts, contains over 100 different proteins, with immunoglobulins being particularly important for treating primary immunodeficiencies. Factors like poor nutrition or malnutrition can result in macro- and micronutrient deficiencies, leading to immunodeficiency. For example, in March 2022, the Allergy, Asthma & Clinical Immunology reported that the most prevalent condition was Common Variable Immunodeficiency (CVID), affecting 16.6% of individuals in the US, 12.9% internationally, and 13.9% globally. Therefore, the increasing prevalence of immune deficiency disorders is contributing to the growth of the blood plasma derivatives market.

The rise in trauma and accident cases is expected to further accelerate the growth of the blood plasma derivatives market. Trauma and accident cases involve situations where individuals suffer physical injuries or harm due to unexpected incidents. Blood plasma derivatives are employed in these scenarios to replace clotting factors, treat hemorrhagic shock, assist in hemostasis and coagulation control, provide fluid replacement, support wound healing, and manage edema while maintaining fluid balance. For instance, in April 2024, the National Highway Traffic Safety Administration, a US government agency, reported that in 2022, 3,308 people were killed, and approximately 289,310 were injured in crashes involving distracted drivers. Thus, the increasing incidence of trauma and accident cases is fueling the growth of the blood plasma derivatives market.

The projected increase in the prevalence of hemophilia is set to be a significant driver propelling the growth of the blood plasma derivatives market. Hemophilia, a hereditary bleeding disorder, hinders proper blood clotting, leading to both spontaneous bleeding and bleeding following injury or surgical procedures. Individuals experiencing hemostasis-related issues, whether hereditary or acquired, often benefit from blood plasma-derived products or medications to effectively manage hemostasis. Treatments for conditions such as hemophilia A, von Willebrand disease, and hemophilia B involve the use of factor VIII, factor VIII/vWF, and factor IX concentrates, respectively. Notably, statistics from the Centers for Disease Control and Prevention (CDC) in August 2022 reported 3.7 cases of hemophilia B and 12 cases of hemophilia A per 100,000 American males in the United States, with 1 in 5,617 male births affected by hemophilia B and 1 in 19,283 male births affected by hemophilia A. Thus, the escalating prevalence of hemophilia serves as a driving force behind the expansion of the blood plasma derivatives market.

Prominent entities within the blood plasma derivatives market are strategically engaging in partnerships to gain a competitive advantage. These strategic alliances aim to ensure patients in need have consistent access to crucial plasma-derived medications, addressing the growing demand for immunoglobulins in France and beyond. A noteworthy example occurred in January 2022 when Kedrion S.p.A., an Italy-based biopharmaceutical company specializing in plasma-derived therapies, collaborated with LPB, a UK-based pharmaceutical company specializing in biological medicinal products. Under this partnership, Kedrion will utilize plasma acquired in France by the Etablissement Francais du Sang (EFS) to manufacture immunoglobulins in Hungary. These immunoglobulins will supplement the current supply available to hospitals nationwide, complying with and operating under the supervision of French health authorities. This import from LFB in France will contribute to reinforcing the supply chain of crucial immunoglobulins, aiding in meeting the healthcare demands of patients.

In April 2022, Grifols S.A., a Spain-based leader in the production of plasma-derived medicines, successfully acquired Biotest AG for an undisclosed amount. This strategic acquisition positions Grifols to enhance the accessibility of plasma medicines for patients, accelerate and broaden its product portfolio, take ownership of the most extensive private European network of plasma facilities boasting 87 locations, and contribute to revenue growth and profitability expansion. Biotest AG, based in Germany, is recognized for its role as a producer of various human blood plasma-derived concentrates used in intensive care medicines

Major companies operating in the blood plasma derivatives market include Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Limited, Meiji Group, Grifols S.A., Shire Pharmaceuticals Inc., GC Biopharma Corp, Emergent BioSolutions Inc., Shanghai Raas Blood Products Co Ltd., Kedrion S.p.A., Sanquin, Biotest AG, Bio Products Ltd., ADMA Biologics Inc., China Biologic Products Holdings Inc., BioIVT, PlasmaGen BioSciences Pvt. Ltd., Virchow Biotech Private Limited, LFB S.A., Intas Pharmaceuticals Ltd., Octapharma Plasma

North America was the largest region in the blood plasma derivatives market in 2024. The regions covered in the blood plasma derivatives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the blood plasma derivatives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The blood plasma derivatives market consists of sales of fibrinogen, globulin, sodium, potassium, bicarbonate, and chloride. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Blood Plasma Derivatives Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on blood plasma derivatives market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for blood plasma derivatives ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The blood plasma derivatives market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Blood Plasma Derivatives Market Characteristics

3. Blood Plasma Derivatives Market Trends And Strategies

4. Blood Plasma Derivatives Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Blood Plasma Derivatives Growth Analysis And Strategic Analysis Framework

6. Blood Plasma Derivatives Market Segmentation

7. Blood Plasma Derivatives Market Regional And Country Analysis

8. Asia-Pacific Blood Plasma Derivatives Market

9. China Blood Plasma Derivatives Market

10. India Blood Plasma Derivatives Market

11. Japan Blood Plasma Derivatives Market

12. Australia Blood Plasma Derivatives Market

13. Indonesia Blood Plasma Derivatives Market

14. South Korea Blood Plasma Derivatives Market

15. Western Europe Blood Plasma Derivatives Market

16. UK Blood Plasma Derivatives Market

17. Germany Blood Plasma Derivatives Market

18. France Blood Plasma Derivatives Market

19. Italy Blood Plasma Derivatives Market

20. Spain Blood Plasma Derivatives Market

21. Eastern Europe Blood Plasma Derivatives Market

22. Russia Blood Plasma Derivatives Market

23. North America Blood Plasma Derivatives Market

24. USA Blood Plasma Derivatives Market

25. Canada Blood Plasma Derivatives Market

26. South America Blood Plasma Derivatives Market

27. Brazil Blood Plasma Derivatives Market

28. Middle East Blood Plasma Derivatives Market

29. Africa Blood Plasma Derivatives Market

30. Blood Plasma Derivatives Market Competitive Landscape And Company Profiles

31. Blood Plasma Derivatives Market Other Major And Innovative Companies

32. Global Blood Plasma Derivatives Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Blood Plasma Derivatives Market

34. Recent Developments In The Blood Plasma Derivatives Market

35. Blood Plasma Derivatives Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기